Everolimus in metastatic renal cell carcinoma after failure of initial anti–VEGF therapy: final results of a noninterventional studyLothar Bergmann, Michael Staehler, Peter J. Goebell et al.|BMC Cancer|2015Cited by 23
Everolimus as second-line therapy for metastatic renal cell carcinoma (mRCC) after one previous VEGF-targeted therapy: Final results of the noninterventional change study.Peter J. Goebell, Lothar Bergmann, Ulrich Kube et al.|Journal of Clinical Oncology|2014Cited by 5